As the Ebola outbreak rages, new treatments are headed into trials. Will they work?

The strain causing the current outbreak has no approved treatments or vaccines but global organizations are rushing to change that.

By Alexandra Pecci • July 20, 2026

Long days, dinners with copious alcohol, and the hunt for emerging assets in China

Why building relationships, navigating cultural nuances and preparing for different deal structures are key to investing in China’s promising drugs.

By Meagan Parrish • July 17, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

This startup thinks humans in clinical trials could become a ‘formality’

Deep Origin is attempting to create “virtual humans” that could one day reduce late-stage safety failures and the need for animal testing.

By Alexandra Pecci • July 16, 2026

How well are AI-discovered drugs faring in the clinic?

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.

By Kelly Bilodeau • July 15, 2026

Galimedix is keeping the amyloid hypothesis alive

The right target but the wrong approach? Why Galimedix’s co-founder believes the company has found an edge in treating Alzheimer’s disease with an amyloid drug.

By Kelly Bilodeau • July 14, 2026

Biotech funding gap widens despite rebound in VC investment

Nearly 70 venture-backed biotech startups raised more than $9.1 billion between January and June, but the majority already had drugs in testing.

By Gwendolyn Wu • July 14, 2026

Moderna, Takeda and Capricor on the verge of notching big drug approvals

Two of the companies are taking a second-go at FDA approval this summer, while another hopes to cement its leader-status in the battle to bring a new sleep treatment to market.

By Alexandra Pecci • July 13, 2026

What pharma leaders wish they knew on day 1

PharmaVoice checked in with four life sciences executives after they landed a new role. Now they’re looking back on what they learned.

By Alexandra Pecci • July 9, 2026

HHS plan to speed drug R&D won’t remove ‘self-inflicted’ delays

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

By Kelly Bilodeau • July 8, 2026

Can anyone catch up to Eli Lilly?

While rivals scramble to replace lost revenue, Lilly is opening an unprecedented gap by being a “contrarian,” as one expert says.

By Kelly Bilodeau • July 7, 2026

Beyond Boston: Unlikely cities stake biotech claims

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

By Alexandra Pecci • July 6, 2026

Doctor-turned-dealmaker reveals his M&A playbook

Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.

By Kelly Bilodeau • July 1, 2026

These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.

Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.

By Kelly Bilodeau • June 30, 2026

3 late-stage MASH drugs that could rival Rezdiffra

The red-hot market has plenty of room for additional therapies from big name players and clinical stage companies alike.

By Alexandra Pecci • June 29, 2026

BIO 2026: Where pharma leaders say AI hasn’t delivered

AI hasn’t always been what it was cracked up to be in pharma. Here’s where execs say the technology hasn’t lived up to the hype.

By Meagan Parrish • June 26, 2026

A ‘nightmare bacteria’ is surging while investment in antibiotics lags

Experts are sounding the alarm about the rise in drug-resistant superbugs and urging more action.

By Kelly Bilodeau • June 25, 2026

HHS, responding to China’s rise, moves to fast-track early drug research

A series of newly planned reforms are designed to entice companies to start early trials in the U.S. rather than overseas.

By Jonathan Gardner • June 24, 2026

Backed by Sanofi and Roche, Orano Med chases radiopharma leadership

Orano Med’s industrial platform offers “unlimited” and unique access to the cancer-fighting alpha emitter lead-212.

By Alexandra Pecci • June 22, 2026

A new Westlake-backed biotech takes aim at migraines

Vedana Therapeutics recently emerged from stealth with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention.

By Jacob Bell • June 18, 2026

Why ivermectin is in the limelight again

As patient interest rises for using the antiparasitic drug in cancer, it's having an impact on R&D in the space.

By Kelly Bilodeau • June 17, 2026

Corvus CEO thinks his next blockbuster is an ITK inhibitor

It’s like “Rituxan all over again,” said CEO Richard Miller, who believes Corvus’ lead candidate could make an impact in both cancer and autoimmune diseases.

By Alexandra Pecci • June 16, 2026

How Lilly is defending its GLP empire

Eli Lilly's recent GLP-2 deal with Hanmi Pharm is another step in the drugmaker’s quest to grow its GLP franchise beyond weight loss and deepen its push into gastrointestinal disease.

By Alivia Kaylor • June 16, 2026

Astellas taps AI to reshape clinical programs as rising stars emerge

As it prepares to compete in the KRAS arena, the Japanese pharma has retooled its approach to clinical development.

By Meagan Parrish • June 12, 2026

Competition is brewing between ADCs and bispecifics

The dueling modalities are each gaining traction in lung cancer. But will they ultimately become allies?

By Kelly Bilodeau • June 11, 2026

With a promising MASH asset, muscle-sparing GLP-1 and new CEO, Rivus gets ready to make its mark

Rivus Pharmaceuticals’ CEO Jorge Bartolome said the biotech is on track to build a “truly differentiated” cardiometabolic portfolio.

By Alexandra Pecci • June 9, 2026